AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study

AtaiBeckley Inc (NASDAQ:ATAI) is among the 13 best NASDAQ penny stocks to buy according to analysts. On February 26, AtaiBeckley Inc (NASDAQ:ATAI) reported topline results from a Phase 2a trial of its drug candidate EMP-01 (oral R-MDMA), which is aimed for treating social anxiety disorder. According to AtaiBeckley, the study met its primary objectives, with EMP-01 showing efficacy signals with a favorable safe profile. In the US alone, social anxiety disorder is estimated to affect 30 million adults. The ...